The Efficacy and Safety of FSK0808, Filgrastim Biosimilar: A Multicenter, Non-randomized Study in Japanese Patients with Breast Cancer - Sagara, Y.; Sato, K.; Fukuma, E.; Higaki, K.; Mizutani, M.; Osaki, A.; Takano, T.; Tokuda, Y.; Ohno, S.; Masuda, N.; Suzuki, M.; Saeki, T. (Japanese journal of clinical oncology, 2013)
Keywords: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Biosimilar Pharmaceuticals - therapeutic use; Breast Neoplasms - chemically induced; Breast Neoplasms - drug therapy; Breast Neoplasms - etiology; Cyclophosphamide - adverse effects; Drug-Related Side Effects and Adverse Reactions - drug therapy; Drug-Related Side Effects and Adverse Reactions - prevention & control; Epirubicin - adverse effects; Female; Filgrastim; Fluorouracil - adverse effects; Granulocyte Colony-Stimulating Factor - administration & dosage; Granulocyte Colony-Stimulating Factor - adverse effects; Granulocyte Colony-Stimulating Factor - therapeutic use; Humans; Incidence; Japan - epidemiology; Leukocyte Count; Middle Aged; Neutropenia - chemically induced; Neutropenia - drug therapy; Neutropenia - epidemiology; Neutropenia - prevention & control; Neutrophils - drug effects; Recombinant Proteins; Japan; filgrastim; breast cancer; neutropenia; chemotherapy; biosimilar